U.S. markets open in 8 hours 40 minutes
  • S&P Futures

    3,902.75
    -1.00 (-0.03%)
     
  • Dow Futures

    31,429.00
    +8.00 (+0.03%)
     
  • Nasdaq Futures

    12,031.25
    -9.25 (-0.08%)
     
  • Russell 2000 Futures

    1,771.60
    +1.80 (+0.10%)
     
  • Crude Oil

    110.88
    +1.31 (+1.20%)
     
  • Gold

    1,827.00
    +2.20 (+0.12%)
     
  • Silver

    21.17
    -0.00 (-0.01%)
     
  • EUR/USD

    1.0580
    -0.0007 (-0.06%)
     
  • 10-Yr Bond

    3.1940
    -3.1940 (-100.00%)
     
  • Vix

    26.95
    -27.23 (-100.00%)
     
  • GBP/USD

    1.2270
    -0.0000 (-0.00%)
     
  • USD/JPY

    135.3040
    -0.1420 (-0.10%)
     
  • BTC-USD

    20,762.89
    -485.71 (-2.29%)
     
  • CMC Crypto 200

    451.38
    -10.41 (-2.25%)
     
  • FTSE 100

    7,258.32
    +49.51 (+0.69%)
     
  • Nikkei 225

    26,949.18
    +77.91 (+0.29%)
     

Anavex Life Sciences Announces Its Very First Scientific Educational Video News Release

  • Oops!
    Something went wrong.
    Please try again later.
·3 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
Anavex Life Sciences Corp.
Anavex Life Sciences Corp.

NEW YORK, June 21, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) disorders, today announces Anavex’s very first Educational Video News Release, which can be accessed via Anavex's newsroom.

To access Anavex’s newsroom vist https://www.anavex.com/newsroom.

About Anavex Life Sciences Corp.

Anavex Life Sciences Corp. (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of novel therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) diseases, pain, and various types of cancer. Anavex’s lead drug candidate, ANAVEX®2-73 (blarcamesine), has successfully completed a Phase 2a clinical trial for Alzheimer’s disease, a Phase 2 proof-of-concept study in Parkinson’s disease dementia and both a Phase 2 and a Phase 3 study in adult patients with Rett syndrome. ANAVEX®2-73 is an orally available drug candidate that restores cellular homeostasis by targeting sigma-1 and muscarinic receptors. Preclinical studies demonstrated its potential to halt and/or reverse the course of Alzheimer’s disease. ANAVEX®2-73 also exhibited anticonvulsant, anti-amnesic, neuroprotective, and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy. The Michael J. Fox Foundation for Parkinson’s Research previously awarded Anavex a research grant, which fully funded a preclinical study to develop ANAVEX®2-73 for the treatment of Parkinson’s disease. ANAVEX®3-71, which targets sigma-1 and muscarinic M1 receptors, is a promising clinical stage drug candidate demonstrating disease-modifying activity against the major hallmarks of Alzheimer’s disease in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid, and tau pathologies. In preclinical trials, ANAVEX®3-71 has shown beneficial effects on mitochondrial dysfunction and neuroinflammation. Further information is available at www.anavex.com. You can also connect with the company on Twitter, Facebook, Instagram and LinkedIn.

Forward-Looking Statements

Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks set forth in the Company’s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Anavex Life Sciences Corp. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.

For Further Information:

Anavex Life Sciences Corp.
Research & Business Development
Toll-free: 1-844-689-3939
Email: info@anavex.com

Investors:
Andrew J. Barwicki
Investor Relations
Tel: 516-662-9461
Email: andrew@barwicki.com